Heart drug mavacamten under microscope: can it reshape damaged heart muscle?
NCT ID NCT06112743
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 4 study tests the drug mavacamten in 63 adults with a type of heart muscle disease called obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve heart structure, measured by MRI, and ease symptoms like shortness of breath. Participants take mavacamten for 48 weeks, and researchers track changes in heart chamber size and muscle thickness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mavacamten
What this could lead to
If successful, this could show that mavacamten improves heart structure and function, potentially leading to better symptom control and quality of life for people with this condition.
What could go wrong
This is a small, single-arm study with no placebo group, so results may be less reliable. The drug may not produce meaningful changes in heart structure or symptoms for all participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOMYOPATHY, HYPERTROPHIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
Montreal, Quebec, H1T 1C8, Canada
-
Local Institution - 0003
Atlanta, Georgia, 30309, United States
-
Local Institution - 0005
Melbourne, Victoria, 3004, Australia
-
Local Institution - 0015
Camperdown, New South Wales, 2050, Australia
-
Local Institution - 0017
Houston, Texas, 77030, United States
-
Local Institution - 0024
Zürich (de), 8091, Switzerland
-
Local Institution - 0025
Leeds, Yorkshire, LS1 3EX, United Kingdom
-
Local Institution - 0029
Lugano, Ticino (it), 6900, Switzerland
-
Local Institution - 0035
Murray, Utah, 84107-5701, United States
-
Local Institution - 0058
Lucerne, Luzern (de), 6000, Switzerland
-
Local Institution - 0061
Geneva, 1205, Switzerland
-
Local Institution - 0068
Québec, Quebec, G1V 4G5, Canada
-
Local Institution - 0074
Rosario, Santa Fe Province, S2000GAP, Argentina
-
Local Institution - 0075
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1428ART, Argentina
-
Local Institution - 0076
Ciudad Autónoma de Buenos Aires, Buenos Aires, 1093, Argentina
-
Local Institution - 0077
Córdoba, Córdoba Province, X5021FPQ, Argentina
-
Local Institution - 0079
Pilar, Buenos Aires, B1629ODT, Argentina
-
Local Institution - 0080
Buenos Aires, 1199, Argentina
-
Local Institution - 0085
Chermside, Queensland, 4032, Australia
-
Local Institution - 0086
Pittsburgh, Pennsylvania, 15212-4756, United States
-
Local Institution - 0087
West Hollywood, California, 90048-1804, United States
-
Local Institution - 0090
Cleveland, Ohio, 44106, United States
-
Local Institution - 0093
Boston, Massachusetts, 02114, United States